BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 17898800)

  • 1. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
    Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to: Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Morgentaler A
    Int J Impot Res; 2008; 20(3):331; author reply 332. PubMed ID: 18475269
    [No Abstract]   [Full Text] [Related]  

  • 4. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel.
    Marbury T; Hamill E; Bachand R; Sebree T; Smith T
    Biopharm Drug Dispos; 2003 Apr; 24(3):115-20. PubMed ID: 12673669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
    Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
    J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testim 1% testosterone gel for the treatment of male hypogonadism.
    Bouloux P
    Clin Ther; 2005 Mar; 27(3):286-98. PubMed ID: 15878382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption of testosterone gel 1% (Testim) from three different application sites.
    Guay AT; Smith TM; Offutt LA
    J Sex Med; 2009 Sep; 6(9):2601-10. PubMed ID: 19549089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.
    Behre HM; Heinemann L; Morales A; Pexman-Fieth C
    Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Testosterone Topical Solution in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel.
    Burns PR; Kim ED; Ruff DD; Seftel AD
    Am J Mens Health; 2018 May; 12(3):524-530. PubMed ID: 26438471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS).
    Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
    Aging Male; 2012 Mar; 15(1):14-21. PubMed ID: 22092151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
    Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
    J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism.
    Liao CH; Wu YN; Lin FY; Tsai WK; Liu SP; Chiang HS
    Andrology; 2013 Jul; 1(4):563-9. PubMed ID: 23653307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease.
    Tan RS; Pu SJ
    Aging Male; 2003 Mar; 6(1):13-7. PubMed ID: 12809076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function.
    Chiang HS; Hwang TI; Hsui YS; Lin YC; Chen HE; Chen GC; Liao CH
    Int J Impot Res; 2007; 19(4):411-7. PubMed ID: 17538639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy.
    Lanfranco F; Zitzmann M; Simoni M; Nieschlag E
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):500-7. PubMed ID: 15049966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.